|
1
|
Klingelhöfer D, Zhu Y, Braun M, Brüggmann
D, Schöffel N and Groneberg DA: A world map of esophagus cancer
research: A critical accounting. J Transl Med. 17:1502019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abnet CC, Arnold M and Wei WQ:
Epidemiology of esophageal squamous cell carcinoma.
Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kelly RJ: Emerging multimodality
approaches to treat localized esophageal cancer. J Natl Compr Canc
Netw. 17:1009–1014. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gronnier C and Collet D: New trends in
esophageal cancer management. Cancers (Basel). 13:30302021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martin-Perez M, Urdiroz-Urricelqui U,
Bigas C and Benitah SA: The role of lipids in cancer progression
and metastasis. Cell Metab. 34:1675–1699. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lambert G, Sjouke B, Choque B, Kastelein
JJP and Hovingh GK: The PCSK9 decade. J Lipid Res. 53:2515–2524.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahboobnia K, Pirro M, Marini E, Grignani
F, Bezsonov EE, Jamialahmadi T and Sahebkar A: PCSK9 and cancer:
Rethinking the link. Biomed Pharmacother. 140:1117582021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonaventura A, Vecchié A, Ruscica M,
Grossi F and Dentali F: PCSK9 as a new player in cancer: New
opportunity or red herring? Curr Med Chem. 29:960–969. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang SZ, Zhu XD, Feng LH, Li XL, Liu XF,
Sun HC and Tang ZY: PCSK9 promotes tumor growth by inhibiting tumor
cell apoptosis in hepatocellular carcinoma. Exp Hematol Oncol.
10:252021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Li S, Luo H, Lu Q and Yu S: PCSK9
promotes the progression and metastasis of colon cancer cells
through regulation of EMT and PI3K/AKT signaling in tumor cells and
phenotypic polarization of macrophages. J Exp Clin Cancer Res.
41:3032022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu B, Li S, Fang Y, Zou Y, Song D, Zhang S
and Cai Y: Proprotein convertase subtilisin/kexin type 9 promotes
gastric cancer metastasis and suppresses apoptosis by facilitating
mapk signaling pathway through HSP70 up-regulation. Front Oncol.
10:6096632020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jurisic V: Multiomic analysis of cytokines
in immuno-oncology. Expert Rev Proteomics. 17:663–674. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moody SE, Perez D, Pan TC, Sarkisian CJ,
Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD and
Chodosh LA: The transcriptional repressor Snail promotes mammary
tumor recurrence. Cancer Cell. 8:197–209. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gravdal K, Halvorsen OJ, Haukaas SA and
Akslen LA: A switch from E-cadherin to N-cadherin expression
indicates epithelial to mesenchymal transition and is of strong and
independent importance for the progress of prostate cancer. Clin
Cancer Res. 13:7003–7011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baumgart E, Cohen MS, Silva Neto B, Jacobs
MA, Wotkowicz C, Rieger-Christ KM, Biolo A, Zeheb R, Loda M,
Libertino JA and Summerhayes IC: Identification and prognostic
significance of an epithelial-mesenchymal transition expression
profile in human bladder tumors. Clin Cancer Res. 13:1685–1694.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye X, Tam WL, Shibue T, Kaygusuz Y,
Reinhardt F, Ng Eaton E and Weinberg RA: Distinct EMT programs
control normal mammary stem cells and tumour-initiating cells.
Nature. 525:256–260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rhim AD, Mirek ET, Aiello NM, Maitra A,
Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK,
Vonderheide RH, et al: EMT and dissemination precede pancreatic
tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Propper DJ and Balkwill FR: Harnessing
cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol.
19:237–253. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnson-Holiday C, Singh R, Johnson E,
Singh S, Stockard CR, Grizzle WE and Lillard JW Jr: CCL25 mediates
migration, invasion and matrix metalloproteinase expression by
breast cancer cells in a CCR9-dependent fashion. Int J Oncol.
38:1279–1285. 2011.PubMed/NCBI
|
|
21
|
Niu Y, Tang D, Fan L, Gao W and Lin H:
CCL25 promotes the migration and invasion of non-small cell lung
cancer cells by regulating VEGF and MMPs in a CCR9-dependent
manner. Exp Ther Med. 19:3571–3580. 2020.PubMed/NCBI
|
|
22
|
Zhang Z, Sun T, Chen Y, Gong S, Sun X, Zou
F and Peng R: CCL25/CCR9 signal promotes migration and invasion in
hepatocellular and breast cancer cell lines. DNA Cell Biol.
35:348–357. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng Y, Sang M, Liu F, Gu L, Li J, Wu Y
and Shan B: Aprepitant inhibits the progression of esophageal
squamous cancer by blocking the truncated neurokinin-1 receptor.
Oncol Rep. 50:1312023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scherbakov AM, Vorontsova SK, Khamidullina
AI, Mrdjanovic J, Andreeva OE, Bogdanov FB, Salnikova DI, Jurisic
V, Zavarzin IV and Shirinian VZ: Novel pentacyclic derivatives and
benzylidenes of the progesterone series cause anti-estrogenic and
antiproliferative effects and induce apoptosis in breast cancer
cells. Invest New Drugs. 41:142–152. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Prasad K and Prabhu GK: Image analysis
tools for evaluation of microscopic views of immunohistochemically
stained specimen in medical research-a review. J Med Syst.
36:2621–2631. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng C, Geng F, Cheng X and Guo D: Lipid
metabolism reprogramming and its potential targets in cancer.
Cancer Commun (Lond). 38:272018.PubMed/NCBI
|
|
28
|
Diao XY and Lin T: Progress in therapeutic
strategies based on cancer lipid metabolism. Thorac Cancer.
10:1741–1743. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nickels JT Jr: New links between lipid
accumulation and cancer progression. J Biol Chem. 293:6635–6636.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fasolato S, Pigozzo S, Pontisso P, Angeli
P, Ruscica M, Savarino E, De Martin S, Lupo MG and Ferri N: PCSK9
levels are raised in chronic HCV patients with hepatocellular
carcinoma. J Clin Med. 9:31342020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mbikay M, Sirois F, Gyamera-Acheampong C,
Wang GS, Rippstein P, Chen A, Mayne J, Scott FW and Chrétien M:
Variable effects of gender and Western diet on lipid and glucose
homeostasis in aged PCSK9-deficient C57BL/6 mice CSK9PC57BL/6. J
Diabetes. 7:74–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ito M, Hiwasa T, Oshima Y, Yajima S,
Suzuki T, Nanami T, Sumazaki M, Shiratori F, Funahashi K, Li SY, et
al: Association of serum anti-PCSK9 antibody levels with favorable
postoperative prognosis in esophageal cancer. Front Oncol.
11:7080392021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu W and Kang Y: Epithelial-mesenchymal
plasticity in cancer progression and metastasis. Dev Cell.
49:361–374. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Donaher JL, Das S, Li X,
Reinhardt F, Krall JA, Lambert AW, Thiru P, Keys HR, Khan M, et al:
Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as
regulators of distinct EMT trajectories that contribute
differentially to metastasis. Nat Cell Biol. 24:554–564. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jurisic V, Srdic-Rajic T, Konjevic G,
Bogdanovic G and Colic M: TNF-α induced apoptosis is accompanied
with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr
Biol. 239:115–122. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu X and Tian X: Long noncoding RNA
TCONS_00068220 promotes breast cancer progression by regulating
epithelial-mesenchymal transition marker E-cadherin. Med Sci Monit.
27:e9298322021.PubMed/NCBI
|
|
37
|
Sharma PK, Singh R, Novakovic KR, Eaton
JW, Grizzle WE and Singh S: CCR9 mediates PI3K/AKT-dependent
antiapoptotic signals in prostate cancer cells and inhibition of
CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.
Int J Cancer. 127:2020–2030. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stankovic S, Konjevic G, Gopcevic K, Jovic
V, Inic M and Jurisic V: Activity of MMP-2 and MMP-9 in sera of
breast cancer patients. Pathol Res Pract. 206:241–247. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li J, Muhammad J, Xie T, Sun J, Lei Y, Wei
Z, Pan S, Qin H, Shao L, Jiang D and Zhang Q: LINC00853 restrains T
cell acute lymphoblastic leukemia invasion and infiltration by
regulating CCR9/CCL25. Mol Immunol. 140:267–275. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li J, Zhao C, Wang D, Wang S, Dong H, Wang
D, Yang Y, Li J, Cui F, He X and Qin J: ZIM3 activation of CCL25
expression in pulmonary metastatic nodules of osteosarcoma recruits
M2 macrophages to promote metastatic growth. Cancer Immunol
Immunother. 72:903–916. 2023. View Article : Google Scholar : PubMed/NCBI
|
